UBS analyst Damian Karas maintains Zebra Technologies (NASDAQ:ZBRA) with a Buy and lowers the price target from $510 to $495.
Seattle Genetics Q2 EPS $(0.73) Beats $(0.86) Estimate, Sales $431.70M Miss $437.55M Estimate
Seattle Genetics (NASDAQ:SGEN) reported quarterly losses of $(0.73) per share which beat the analyst consensus estimate of $(0.86) by 15.12 percent. This is a 55.32 percent decrease over losses of $(0.47) per share from
